CN100384875C - 蛋白质 - Google Patents

蛋白质 Download PDF

Info

Publication number
CN100384875C
CN100384875C CNB018084885A CN01808488A CN100384875C CN 100384875 C CN100384875 C CN 100384875C CN B018084885 A CNB018084885 A CN B018084885A CN 01808488 A CN01808488 A CN 01808488A CN 100384875 C CN100384875 C CN 100384875C
Authority
CN
China
Prior art keywords
bcmp
antibody
cell
sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018084885A
Other languages
English (en)
Chinese (zh)
Other versions
CN1426307A (zh
Inventor
R·S·博伊德
A·C·斯塔姆普斯
J·A·特雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0004576.5A external-priority patent/GB0004576D0/en
Priority claimed from GB0031341A external-priority patent/GB0031341D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of CN1426307A publication Critical patent/CN1426307A/zh
Application granted granted Critical
Publication of CN100384875C publication Critical patent/CN100384875C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CNB018084885A 2000-02-25 2001-02-21 蛋白质 Expired - Fee Related CN100384875C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004576.5 2000-02-25
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
GB0031341.1 2000-12-21
GB0031341A GB0031341D0 (en) 2000-12-21 2000-12-21 Protein

Publications (2)

Publication Number Publication Date
CN1426307A CN1426307A (zh) 2003-06-25
CN100384875C true CN100384875C (zh) 2008-04-30

Family

ID=26243736

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018084885A Expired - Fee Related CN100384875C (zh) 2000-02-25 2001-02-21 蛋白质

Country Status (14)

Country Link
US (3) US20030130214A1 (enExample)
EP (2) EP1259604A1 (enExample)
JP (1) JP2003524017A (enExample)
KR (1) KR100740761B1 (enExample)
CN (1) CN100384875C (enExample)
AT (1) ATE352311T1 (enExample)
AU (3) AU2001233913A1 (enExample)
BR (1) BR0108659A (enExample)
CA (1) CA2399999A1 (enExample)
DE (1) DE60126248T2 (enExample)
ES (1) ES2279801T3 (enExample)
IL (1) IL151448A0 (enExample)
NZ (1) NZ520967A (enExample)
WO (2) WO2001062914A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
GB0125072D0 (en) * 2001-10-18 2001-12-12 Oxford Glycosciences Uk Ltd Protein
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
US20040033530A1 (en) * 2002-04-08 2004-02-19 Awrey Donald E. High throughput purification, characterization and identification of recombinant proteins
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
JP2006526382A (ja) * 2002-12-06 2006-11-24 シンガポール ジェネラル ホスピタル ピーティーイー リミテッド 中枢神経系の損傷
WO2005029083A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent
WO2005034994A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 固形腫瘍治療剤
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
KR101398079B1 (ko) * 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN104447975A (zh) * 2014-11-18 2015-03-25 深圳市人口和计划生育科学研究所 一种提取人肿瘤细胞膜蛋白的方法
WO2017011375A1 (en) * 2015-07-10 2017-01-19 University Of Iowa Reseaarch Foundation Bst-2 as a therapeutic target and a predictive/prognostic bio-signature for breast cancer growth and metastasis
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007749A1 (en) * 1996-08-23 1998-02-26 Human Genome Sciences, Inc. Novel human growth factors
WO1999047669A2 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus brusttumorgewebe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516381A (en) * 1999-06-30 2004-03-26 Corixa Corp Lung tumor proteins in the therapy and diagnosis of lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007749A1 (en) * 1996-08-23 1998-02-26 Human Genome Sciences, Inc. Novel human growth factors
WO1999047669A2 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus brusttumorgewebe

Also Published As

Publication number Publication date
DE60126248T2 (de) 2007-07-05
WO2001062784A2 (en) 2001-08-30
NZ520967A (en) 2004-04-30
HK1056692A1 (zh) 2004-02-27
AU2001233929B2 (en) 2005-09-08
KR20030007440A (ko) 2003-01-23
AU2001233913A1 (en) 2001-09-03
CA2399999A1 (en) 2001-08-30
WO2001062914A1 (en) 2001-08-30
ATE352311T1 (de) 2007-02-15
ES2279801T3 (es) 2007-09-01
AU3392901A (en) 2001-09-03
US20070212368A1 (en) 2007-09-13
EP1259604A1 (en) 2002-11-27
WO2001062784A3 (en) 2002-01-31
DE60126248D1 (de) 2007-03-15
CN1426307A (zh) 2003-06-25
AU2001233929C1 (en) 2006-03-02
BR0108659A (pt) 2002-11-05
KR100740761B1 (ko) 2007-07-19
US20030130214A1 (en) 2003-07-10
EP1257285A2 (en) 2002-11-20
US20030099662A1 (en) 2003-05-29
IL151448A0 (en) 2003-04-10
EP1257285B1 (en) 2007-01-24
JP2003524017A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
CN100384875C (zh) 蛋白质
CN101555283A (zh) 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
WO2003087831A2 (en) Proteins involved in breast cancer
HK1202299A1 (en) Novel cancer-associated antigen
CN1726393B (zh) 用于检测癌症及其前体病变的化合物和方法
AU2001233929A1 (en) Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
JP2003507027A (ja) タンパク質、遺伝子ならびに乳癌の診断及び処置へのこれらの使用
EP1266225A2 (en) Diagnosis and treatment of breast cancer
US20100015152A1 (en) Diagnostic and therapeutic methods
ES2249410T3 (es) Bcmp-7 como marcador para el diagnostico de cancer de pecho.
US9134314B2 (en) Methods for diagnosing and treating cancers
AU2005218046B2 (en) Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
HK1056692B (en) Proteins
US20040166517A1 (en) Cancer associated protein
US20040053830A1 (en) BCMP84 protein, compositions, diagnostic and therapeutic uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1056692

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080430

Termination date: 20100221